KRAS Biomarkers
Amoy Diagnostics, Amgen Partner on Lung Cancer CDx Development for Lumakras in Japan
Amoy Diagnostics will develop its PCR-based panel as a companion diagnostic in Japan to screen NSCLC patients for Amgen's KRAS G12C inhibitor.
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug
The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C.
Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC
As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status.
Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor
Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.